ORIC Pharmaceuticals, Inc. ORIC
7.82 USD -0.04 (-0.51%)
As ofNov 16, 2026, 11:00 AM EST
7.62 Day range 7.92
7.23 52-week range 14.68
- YTD
- -4.40%
- 1 year
- -36.16%
News
benzinga.com BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.
benzinga.com Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14 Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…benzinga.com Stifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18 Stifel analyst Laura Prendergast maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $14 to $18.
benzinga.com ORIC Plans Global Phase 3 Redwood-1 Trial Of Enozertinib In 1L EGFR Atypical NSCLC In 1H 2027 After Phase 1b Showing 84% Confirmed Systemic ORR, 70% Confirmed Intracranial ORR In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and…
